|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.80 USD | -0.48% |
|
+0.32% | +98.10% |
| 05-14 | Fortress Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 04-21 | Journey Medical Corporation secures contract with third major GPO for Emrosi | RE |
Company Valuation: Fortress Biotech, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 249.1 | 71.14 | 54.57 | 55.9 | 113.6 | 108.6 | - |
| Change | - | -71.44% | -23.29% | 2.43% | 103.22% | -4.38% | - |
| Enterprise Value (EV) | 249.1 | 71.14 | 54.57 | 55.9 | 113.6 | 108.6 | 108.6 |
| Change | - | -71.44% | -23.29% | 2.43% | 103.22% | -4.38% | 0% |
| P/E | -3.16x | -0.68x | -0.36x | -0.75x | -52.3x | 1.36x | -6.54x |
| PBR | - | - | - | - | - | - | - |
| PEG | - | -0x | 0x | 0x | 0.5x | -0x | 0x |
| Capitalization / Revenue | 3.62x | 0.94x | 0.65x | 0.97x | 1.8x | 1.36x | 0.88x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 1.36x | 0.88x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -6.04x | -57.9x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -11.85 | -14.55 | -8.47 | -2.69 | -0.07 | 2.4 | -0.5 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 68.79 | 75.74 | 84.51 | 57.68 | 63.26 | 79.88 | 123 |
| EBITDA | -188.5 | - | - | -107.3 | -65.56 | - | - |
| EBIT 1 | -188.5 | -203.6 | -142.3 | -110.4 | -70.22 | -17.98 | -1.875 |
| Net income 1 | -64.7 | -86.58 | -68.67 | -46 | -1.882 | 90.51 | -20.84 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 37.500 | 9.825 | 3.010 | 2.025 | 3.660 | 3.270 | 3.270 |
| Nbr of stocks (in thousands) | 6,642 | 7,241 | 18,131 | 27,605 | 31,038 | 33,219 | - |
| Announcement Date | 3/28/22 | 3/30/23 | 3/28/24 | 3/31/25 | 3/31/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 17.64x | 3.78x | 9.76x | 0.58% | 67.88B | |
| 26.33x | 5.45x | 16.01x | 0.6% | 53.23B | |
| 37.7x | 12.83x | 24.43x | -.--% | 48.71B | |
| -43.2x | 3.1x | 9.18x | 3.5% | 38.98B | |
| 24.81x | 3.46x | 11.92x | -.--% | 29.55B | |
| 67.61x | 3.45x | 25.63x | -.--% | 23.75B | |
| -6.42x | 8.92x | -5.49x | -.--% | 22.07B | |
| 64.54x | 6.33x | 43.58x | -.--% | 19.84B | |
| 24.4x | 5.22x | 13.67x | -.--% | 16.57B | |
| Average | 23.71x | 5.84x | 16.52x | 0.52% | 35.62B | |
| Weighted average by Cap. | 20.69x | 5.88x | 15.57x | 0.65% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- FBIO Stock
- FBIOP Stock
- Valuation Fortress Biotech, Inc.
Select your edition
All financial news and data tailored to specific country editions
